Galmed Pharmaceutica (GLMD)
$0.39
0.04 (9.97%)
GLMD Stock Quote Delayed 30 Minutes
Hottest Manufacturing Stocks Now – BSPM GLMD NAII PBYI
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.95M
PE Ratio
0.27
EPS
1.41
Volume (Avg. Vol.)
86,173
Day's Range
$0.34 - $0.39
52-Week Range
$0.26 - $5.63
Dividend & Yield
N/A (N/A)
GLMD Stock Predictions, Articles, and Galmed Pharmaceutica News
10 Biotechnology Stocks to Sell Now
This week, the overall grades of 10 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Biggest Movers in Manufacturing Stocks Now – FLXN ASX MLSS SPIL
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
Biggest Movers in Manufacturing Stocks Now – XNPT AIXG CLDX RLYP
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
27 Biotechnology Stocks to Sell Now
The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
6 Biotechnology Stocks to Buy Now
This week, six biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
Biotech Stocks With Upside Target Ebola, Liver Disease
Developing successful Ebola and liver disease treatments is an incredibly risky opportunity for biotech stocks to create value.
